FLT3 and acute myeloid leukemia: Levis et al. showed that Gilteritinib was beneficial as post-HSCT maintenance in adults with FLT3-ITD AML who had detectable MRD, resulting in a significant RFS benefit, particularly in this MRD-positive subgroup [172].